Peripheral Blood MicroRNA Expression Profiles in Alzheimer's Disease: Screening, Validation, Association with Clinical Phenotype and Implications for Molecular Mechanism
Related Experiment Video
Updated: Mar 31, 2026
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
Ru-Jing Ren1, Yong-Fang Zhang2, Eric B Dammer3
1Department of Neurology & Neuroscience Institute, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Abstract:
A series of investigations have been performed regarding microRNA (miRNA, miR) of Alzheimer's disease (AD) patients. However, most of these used microarray with neither validation by PCR nor any follow-up on the biological mechanism implicated by findings. Further, there were rarely any analyses linking clinical phenotype of de novo, drug-naive patients to cellular pathogenic mechanism(s) to date. Microarray screening followed by validation via quantitative PCR (Q-PCR) assays and the relationship between miRNAs and phenotypic indices were evaluated. Additionally, the cellular mechanism of miRNAs through effects of β-site amyloid precursor protein (APP) cleaving enzyme (BACE1) was assessed. We identified 2 specific differentially expressed (DE) miRNAs (miR-339 and miR-425) as potential diagnostic biomarkers for AD and revealed that these DE miRNAs could be involved in modulating the pathogenesis of AD via BACE1 protein inhibition. The findings presented here reveal a detailed snapshot of the profile of peripheral blood mononuclear cells (PBMC) miRNA changes in AD patients, association with clinical phenotype, and potential roles in cellular pathogenesis.
Insights
Researchers identified two microRNAs (miRNAs) as potential Alzheimer's disease (AD) biomarkers. These miRNAs may regulate AD pathogenesis by inhibiting BACE1, offering new diagnostic and therapeutic insights for Alzheimer's disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Previous Alzheimer's disease (AD) research often lacked miRNA validation and mechanistic insight.
- Limited studies linked de novo, drug-naive patient phenotypes to cellular mechanisms of AD pathogenesis.
Purpose of the Study:
- To identify and validate microRNAs (miRNAs) as diagnostic biomarkers for Alzheimer's disease (AD).
- To investigate the association between miRNA expression and clinical phenotypes in AD patients.
- To explore the cellular mechanisms of miRNA involvement in AD pathogenesis, focusing on BACE1.
Main Methods:
- Microarray screening to identify differentially expressed miRNAs in AD patients.
- Quantitative PCR (Q-PCR) assays for miRNA validation.
- Analysis of miRNA relationships with clinical phenotypic indices and BACE1 effects.
Main Results:
- Identified two specific differentially expressed miRNAs (miR-339 and miR-425) as potential AD diagnostic biomarkers.
- Demonstrated that these miRNAs may modulate AD pathogenesis by inhibiting the β-site APP cleaving enzyme (BACE1).
- Provided a comprehensive profile of peripheral blood mononuclear cell (PBMC) miRNA changes in AD patients.
Conclusions:
- miR-339 and miR-425 are promising peripheral biomarkers for Alzheimer's disease diagnosis.
- These miRNAs potentially regulate AD pathogenesis through BACE1 inhibition, highlighting a novel cellular mechanism.
- Findings offer insights into PBMC miRNA profiles and their association with AD clinical phenotypes.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22MicroRNAs
01:22MicroRNAs
01:22Alzheimer's Disease: Treatment